{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:23:34Z","timestamp":1793381014772,"version":"4.5.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Global Infect Dis"],"published-print":{"date-parts":[[2010]]},"DOI":"10.4103\/0974-777x.62883","type":"journal-article","created":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T01:59:47Z","timestamp":1273111187000},"page":"151","source":"Crossref","is-referenced-by-count":169,"title":["Treatment of visceral leishmaniasis"],"prefix":"10.4103","volume":"2","author":[{"given":"DN","family":"Lockwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EM","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0974-777X.62883-1","unstructured":"World Health Organization. Leishmaniasis Disease Burden. Available from: http:\/\/www.who.int\/leishmaniasis. [Last cited on 2010 January 21]."},{"key":"key-10.4103\/0974-777X.62883-2","first-page":"69","volume-title":"Pharmokinetics of antimony during treatment of visceral leishmaniaisis with sodium stibogluconate or meglumine antimoniate","author":"Chulay","year":"1988","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-3","first-page":"210","volume-title":"Comparison of two dosage schedules of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya","author":"Anabwani","year":"1983","journal-title":"Lancet"},{"key":"key-10.4103\/0974-777X.62883-4","first-page":"296","volume-title":"Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies","author":"Herwaldt","year":"1992","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-5","first-page":"264","volume-title":"Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers","author":"Lawn","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-6","first-page":"664","volume-title":"Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources","author":"Seaman","year":"1996","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/0974-777X.62883-7","first-page":"612","volume-title":"Conflict and kala-azar: Determinants of adverse outcomes of kala-azar among patients in southern Sudan","author":"Collin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-8","first-page":"561","volume-title":"Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as first line drug.An observational study of 80 cases?","author":"Thakur","year":"1998","journal-title":"Ann Trop Med Parasitol"},{"key":"key-10.4103\/0974-777X.62883-9","first-page":"1104","volume-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the centre of the Indian epidemic","author":"Sundar","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-10","first-page":"350","volume-title":"Treatment of visceral leishmaniasis in south eastern Nepal: Decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline","author":"Rijal","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-11","first-page":"131","volume-title":"Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar","author":"Das","year":"2005","journal-title":"Natl Med J India"},{"key":"key-10.4103\/0974-777X.62883-12","first-page":"388","volume-title":"Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya","author":"Moore","year":"2001","journal-title":"Bull World Health Organ"},{"key":"key-10.4103\/0974-777X.62883-13","first-page":"668","volume-title":"Ethiopian visceral leishmaniasis: Generic and proprietary sodium stibogluconate are equivalent: HIV co-infected patients have a poor outcome","author":"Ritmeijer","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-14","first-page":"837","volume-title":"Antimony resistant Leishmania donovani in eastern Sudan: Incidence and in vitro correlation","author":"Abdo","year":"2003","journal-title":"East Mediterr Health J"},{"key":"key-10.4103\/0974-777X.62883-15","first-page":"357","volume-title":"A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection","author":"Ritmeijer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-16","first-page":"54","volume-title":"Visceral leishmaniasis in HIV infected and non HIV infected patients: A comparative study","author":"Pintado","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"key-10.4103\/0974-777X.62883-17","first-page":"21","volume-title":"AmBisome: Liposomal formulation, structure, mechanism of action and preclinical experience","author":"Adler-Moore","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/0974-777X.62883-18","first-page":"179","volume-title":"Effect of tissue penetration on AmBisome efficacy","author":"Adler-Moore","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"key-10.4103\/0974-777X.62883-19","first-page":"377","volume-title":"Amphotericin B treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations","author":"Sundar","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-20","first-page":"625","volume-title":"Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with HIV","author":"Torre-Cisneros","year":"1993","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-21","first-page":"188","volume-title":"Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions","author":"Seaman","year":"1995","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-22","first-page":"560","volume-title":"Liposomal amphotericin B in Mediterranean visceral leishmaniasis: A multicentre trial","author":"Davidson","year":"1994","journal-title":"Quarterly J Medicine"},{"key":"key-10.4103\/0974-777X.62883-23","first-page":"938","volume-title":"Short course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)","author":"Davidson","year":"1996","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-24","first-page":"1599","volume-title":"Amphotericin vs.sodium stibogluconate in first line treatment of Indian kala-azar","author":"Mishra","year":"1994","journal-title":"Lancet"},{"key":"key-10.4103\/0974-777X.62883-25","first-page":"319","volume-title":"Comparison of three treatment regimes with liposomal amphoterecin B (AmBisome) for visceral leishmaniasis in India: A randomized dose-finding study","author":"Thakur","year":"1996","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-26","first-page":"419","volume-title":"Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: Randomized trial","author":"Sundar","year":"2001","journal-title":"BMJ"},{"key":"key-10.4103\/0974-777X.62883-27","first-page":"800","volume-title":"Single dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: A multicentre study","author":"Sundar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-28","first-page":"504","volume-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","author":"Sundar","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0974-777X.62883-29","first-page":"19","volume-title":"Unresponsiveness to AmBisome in some Sudanese patients with kala-azar","author":"Mueller","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-30","unstructured":"Report of a WHO informal consultation on liposomal amphotericin B in the treatment of visceral leishmaniasis. World Health Organization;2005."},{"key":"key-10.4103\/0974-777X.62883-31","first-page":"2633","volume-title":"The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani","author":"Croft","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"key-10.4103\/0974-777X.62883-32","first-page":"1630","volume-title":"Hexadecylphosphocholine: Oral treatment of visceral leishmaniasis in mice","author":"Kuhlencord","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0974-777X.62883-33","first-page":"1821","volume-title":"Trial of oral miltefosine for visceral leishmaniasis","author":"Sundar","year":"1998","journal-title":"Lancet"},{"key":"key-10.4103\/0974-777X.62883-34","first-page":"1795","volume-title":"Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis","author":"Jha","year":"1999","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0974-777X.62883-35","first-page":"1739","volume-title":"Oral miltefosine for Indian visceral leishmaniasis","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0974-777X.62883-36","first-page":"591","volume-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis","author":"Bhattacharya","year":"2007","journal-title":"J Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-37","first-page":"221","volume-title":"Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate","author":"Chunge","year":"1990","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-38","first-page":"653","volume-title":"Paromomycin","author":"Davidson","year":"2009","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-39","first-page":"715","volume-title":"Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone","author":"Seaman","year":"1993","journal-title":"J Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-40","doi-asserted-by":"crossref","unstructured":"Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: A retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 2007;77:89-94.","DOI":"10.4269\/ajtmh.2007.77.89"},{"key":"key-10.4103\/0974-777X.62883-41","first-page":"1200","volume-title":"Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India","author":"Jha","year":"1998","journal-title":"BMJ"},{"key":"key-10.4103\/0974-777X.62883-42","first-page":"2571","volume-title":"Injectable paromomycin for Visceral leishmaniasis in India","author":"Sundar","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0974-777X.62883-43","first-page":"914","volume-title":"Short course paromomycin treatment of visceral leishmaniasis in India: 14 day vs 21-day treatment","author":"Sundar","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-44","unstructured":"Wasuna M. LEAP (Leishmania East Africa Platform). Available from: http:\/\/www.worldleish4.org\/abstracts. [Last cited on 2010 January 21]."},{"key":"key-10.4103\/0974-777X.62883-45","first-page":"1256","volume-title":"Amphoterecin vs pentamidine in antimony- unresponsive kala-azar","author":"Mishra","year":"1992","journal-title":"Lancet"},{"key":"key-10.4103\/0974-777X.62883-46","first-page":"1064","volume-title":"Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: Report of four cases","author":"Patel","year":"2009","journal-title":"Trop Med Int Health"},{"key":"key-10.4103\/0974-777X.62883-47","first-page":"1034","volume-title":"Phase 2 efficacy trial of an oral 8-aminoquinolone (WR6026) for treatment of visceral leishmaniasis","author":"Sherwood","year":"1994","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62883-48","first-page":"685","volume-title":"Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi","author":"Dietze","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-49","first-page":"1005","volume-title":"A phase 2 dose-rating study of sitamiquine for treatment of visceral leishmaniasis in India","author":"Jha","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-50","first-page":"871","volume-title":"A phase 2 dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya","author":"Wasunna","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62883-51","first-page":"928","volume-title":"A policy for leishmaniasis with respect to the prevention and control of drug resistance","author":"Bryceson","year":"2001","journal-title":"Trop Med Int Health"},{"key":"key-10.4103\/0974-777X.62883-52","first-page":"389","volume-title":"Drug unresponsiveness and combination therapy for kala-azar","author":"Jha","year":"2006","journal-title":"Indian J Med Res"},{"key":"key-10.4103\/0974-777X.62883-53","first-page":"835","volume-title":"In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphoterecin B: Correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity","author":"Kumar","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0974-777X.62883-54","first-page":"1000","volume-title":"New treatment approach in Indian visceral leishmaniasis: Single-dose liposomal amphoterecin B followed by short-course oral miltefosine","author":"Sundar","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Global Infectious Diseases"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:51:13Z","timestamp":1786632673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0974-777X.62883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"alternative-id":["62883"],"URL":"https:\/\/doi.org\/10.4103\/0974-777x.62883","relation":{},"ISSN":["0974-777X"],"issn-type":[{"value":"0974-777X","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}